Rules-Based Medicine (RBM) and Psynova will focus on the unmet clinical need for an objective and reliable diagnostic test to accelerate and optimize the treatment of schizophrenia.
Under the terms of the agreement, the companies will collaborate on the validation, regulatory approval and manufacture of a diagnostic blood test for schizophrenia that will be sold worldwide exclusively by RBM.
The co-development agreement will leverage Psynova’s discovery of proprietary biomarkers with RBM’s protein biomarker platform and CLIA-certified central lab service to accelerate the delivery of an objective diagnostic blood test for schizophrenia.
Sabine Bahn, director and co-founder of Psynova, said: “The tests will be a tool to help general practitioners and psychiatrists in the difficult task of diagnosing and treating patients much sooner, ideally, when symptoms are still mild.”